Obesity is the accumulation of excess body fat to such an extent that it has a negative effect on the health. Obesity occurs due to eating more calories than you burn in daily activities and exercise on a long-term basis. When the body mass index (BMI) score is 30 or more, the person is considered obese. BMI is calculated, by taking a person’s weight and height into account. It is widely used as an indicator of excess weight. Some of the common causes of obesity are having a sedentary lifestyle, eating food which is high in calories and fats, no enough sleep which leads to hormonal changes that makes you feel hungrier, as a result of which person the tends to eat more. High consumption of alcohol and desk jobs is also reasons for obesity.
But obesity can be managed by including lifestyle changes, medications or surgery. Dieting and physical exercise play a very crucial role in treating obesity.
By reducing the consumption of energy-dense foods, diet quality can be improved; for instance, high fat or sugars and by increasing the intake of dietary fiber. Along with a suitable diet, medications can be used to reduce appetite or decrease fat absorption. Surgery is the option when diet, exercise and medication are ineffective. A gastric balloon or surgery may be performed to reduce stomach volume or length of the intestines, leading to feeling full earlier or a reduced ability to absorb nutrients from food.
According to WHO, every year in the United States, obesity has been cited as a contributing factor to approximately 100,000–400,000 deaths. In addition, it has increased health care usage and expenditures, which costs the society an estimated $117 billion directly (preventive, diagnostic, and treatment services related to weight) and indirectly (absenteeism, loss of future earnings due to premature death) costs. Health care costs associated with smoking and accounts for 6% to 12% of national health care expenditures.
The American Medical Association classified obesity as a disease in 2013.
Factors Influencing Market Scenario:
According to the Centers for Disease Control and Prevention (CDC) report (2010), 65.7% of American adults and 17% of American children are overweight.
In 2014, CDC figures stated that more than one-third (36.5%) of U.S. adults aged 20 and older and 17% of children and adolescents aged 2–19 years were obese.
In 2015-16, a second study from the National Center for Health Statistics at the CDC showed that 39.6% of US adults aged 20 and older were obese. The proportion was 37.9% for men and 41.1% for women.
Organization for Economic Co-operation and Development (OECD) in 2013 found that 57.6% of American citizens were overweight or obese. The organization estimates that by 2020, 3/4 of the American population will likely be overweight or obese.
Rising incidences of obesity is one of the important drivers for Obesity Treatment Market. Increase in cases of obesity amongst children and growing awareness about the obesity treatment will drive the market. In addition, Research & Development initiatives, technological advancements and improved healthcare facilities are the key factors fueling the growth of the market. Various solutions available in weight Management is expected to fuel industry demand. However, post-surgical side effects and availability of low cost alternatives is the major restraining factor hampering the growth of Obesity Treatment market.
Depending upon the geographical analysis, the market includes major four regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA). Due to increase in demand for drugs, commercialization of minimally invasive surgical procedures, and rise in awareness about risks associated with obesity, Asia Pacific region is expected to witness the growth in the market. Some of the key driving factors in the emerging countries are sedentary lifestyle and unhealthy diet. North America is expected to dominate the market owing to the rise in childhood obesity rates, increase in membership for health clubs, lifestyle changes along with high level of research and development activities which fuel the growth of the market in this region.
The global Obesity Treatment market comprises some of the key players such as Allergan Plc;
Arena Pharmaceuticals, Inc.; Cousin Biotech; Covidien plc ; EnteroMedics, Inc.; Ethicon (Johnson & Johnson Company); F. Hoffmann-La Roche Ltd.; Medtronic; Novo Nordisk A/S; USGI Medical, Inc. and VIVUS, Inc.
• In May 2018, an international research team, in which Deutsches Zentrum fuer Diabetesforschung DZD is participating has identified a novel adipokine which favors the development of insulin resistance and systemic inflammation. This adipokine is secreted by the adipocytes of the abdominal fat tissue and released into the bloodstream, in case of severe obesity. This new finding will contribute to the development of alternative approaches for the treatment of diseases caused by obesity. The results of this research study have been published in the journal Diabetologia (Hörbelt et al, 2018) of the European Association for the Study of Diabetes (EASD).
• In May 2018, Professor Livio Luzi and colleagues, from the ‘Istituto di Ricovero e Cura a Carattere Scientifico Policlinico’ San Donato, Italy, investigated the effects of dTMS on appetite and satiety in obese people. The research team found out a novel way which could help monitor food cravings. According to them, stimulating the brain with magnetic energy can help reduce food cravings in obese people. This would eventually aid in weight loss. Deep Transcranial Magnetic Stimulation (dTMS) is a medical treatment which uses magnetic energy to stimulate neurons in specific areas of the brain. According to Professor Luzi, dTMS could present a much safer and cheaper alternative to treat obesity compared to drugs or surgery. The results of the study were presented in the annual meeting of Barcelona at the European Society of Endocrinology, ECE 2018.
• In May 2018, Novo Nordisk Pharma Korea announced that it has expanded the sales of Saxenda (ingredient: liraglutide 3.0 mg) to 10 general hospitals, including Seoul National University Hospital (SNUH). Saxenda an obesity treatment as a glucagon-like peptide 1 receptor agonist. This drug was released in the month of March. Some of hospitals in which it is available including SNUH are Bundang Seoul National University Hospital, Severance Hospital, Kangbuk Samsung Hospital, Ajou University Hospital, and Soon Chun Hyang University Hospital Seoul. As per the Korea Biomedical review, the general manager of Novo Nordisk Pharma Korea said that the company will make best effort to improve social awareness on obesity and the importance of proper obesity management as well.
Obesity Treatment Market Segmentation
• Appetite Suppressants
• Combination Drugs
• Satiety Drugs
By Surgery & Devices:
• Adjustable Gastric Banding
• Biliopancreatic Diversion With Duodenal Switch
• Endoscopic Procedures
• Roux-en-Y Gastric Bypass
• Sleeve Gastrectomy
o North America
? Rest of Europe
? South Korea
? Rest of Asia-Pacific
? Saudi Arabia
? South Africa
? Rest of LAMEA